Novelix Pharmaceuticals Ltd
₹ 75.8
-5.00%
19 Jun
- close price
About
Incorporated in 1994, Novelix Pharmaceuticals Ltd trades in Pharmaceuticals and related products , shares, and securities[1]
Key Points
- Market Cap ₹ 181 Cr.
- Current Price ₹ 75.8
- High / Low ₹ 92.0 / 29.3
- Stock P/E
- Book Value ₹ 8.89
- Dividend Yield 0.00 %
- ROCE -25.7 %
- ROE -25.0 %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 4.06% over last quarter.
- Company's working capital requirements have reduced from 163 days to 87.7 days
Cons
- Stock is trading at 8.53 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -0.62% over past five years.
- Company has a low return on equity of -21.8% over last 3 years.
- Promoter holding has decreased over last 3 years: -16.4%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.95 | 5.74 | 6.35 | 5.72 | 9.19 | 10.51 | 10.73 | 10.85 | 9.59 | 8.91 | 4.40 | |
| 5.13 | 4.86 | 5.66 | 5.24 | 9.06 | 10.47 | 10.62 | 10.75 | 13.06 | 11.10 | 7.34 | |
| Operating Profit | 0.82 | 0.88 | 0.69 | 0.48 | 0.13 | 0.04 | 0.11 | 0.10 | -3.47 | -2.19 | -2.94 |
| OPM % | 13.78% | 15.33% | 10.87% | 8.39% | 1.41% | 0.38% | 1.03% | 0.92% | -36.18% | -24.58% | -66.82% |
| 0.00 | 0.02 | 0.00 | 0.11 | 0.30 | 0.15 | 0.11 | 0.00 | 0.00 | 0.32 | 0.33 | |
| Interest | 0.01 | 0.01 | 0.01 | 0.00 | 0.05 | 0.16 | 0.13 | 0.12 | 0.07 | 0.06 | 0.00 |
| Depreciation | 0.27 | 0.29 | 0.41 | 0.35 | 0.19 | 0.24 | 0.21 | 0.19 | 0.21 | 0.10 | 0.05 |
| Profit before tax | 0.54 | 0.60 | 0.27 | 0.24 | 0.19 | -0.21 | -0.12 | -0.21 | -3.75 | -2.03 | -2.66 |
| Tax % | 31.48% | 31.67% | 48.15% | 45.83% | 84.21% | 66.67% | 25.00% | 23.81% | 0.27% | -0.49% | |
| 0.38 | 0.42 | 0.15 | 0.13 | 0.03 | -0.35 | -0.15 | -0.26 | -3.76 | -2.03 | -2.54 | |
| EPS in Rs | 0.47 | 0.52 | 0.11 | 0.12 | -0.01 | -0.43 | -0.30 | -0.35 | -4.62 | -2.22 | -2.69 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -6% |
| TTM: | -62% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 54% |
| 3 Years: | 100% |
| 1 Year: | 159% |
| Return on Equity | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -13% |
| 3 Years: | -22% |
| Last Year: | -25% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 |
| Reserves | 2.93 | 3.35 | 3.33 | 3.45 | 3.44 | 3.07 | 2.82 | 2.50 | -1.24 | -0.70 | -0.90 |
| 0.07 | 0.04 | 0.00 | 0.00 | 0.99 | 0.98 | 0.93 | 0.77 | 0.00 | 0.16 | 1.02 | |
| 0.44 | 0.69 | 1.08 | 1.19 | 1.22 | 1.43 | 1.49 | 2.35 | 2.72 | 1.18 | 0.23 | |
| Total Liabilities | 11.54 | 12.18 | 12.51 | 12.74 | 13.75 | 13.58 | 13.34 | 13.72 | 9.58 | 8.74 | 8.45 |
| 1.22 | 1.17 | 0.75 | 0.70 | 2.10 | 2.17 | 1.92 | 1.83 | 1.65 | 2.20 | 2.17 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.02 | 0.05 | 1.14 | 1.69 | 0.33 | 0.63 | 0.49 | 0.30 | 0.39 | 0.42 | 0.42 |
| 10.30 | 10.96 | 10.62 | 10.09 | 11.32 | 10.78 | 10.93 | 11.59 | 7.54 | 6.12 | 5.86 | |
| Total Assets | 11.54 | 12.18 | 12.51 | 12.74 | 13.75 | 13.58 | 13.34 | 13.72 | 9.58 | 8.74 | 8.45 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.45 | 0.05 | 0.30 | 2.05 | -1.82 | 0.37 | -0.53 | 0.63 | 1.59 | 1.59 | |
| 1.06 | 0.73 | -1.40 | -1.06 | 0.21 | -0.64 | 0.43 | 0.45 | 0.14 | -0.76 | |
| 2.40 | 0.17 | -0.01 | 0.22 | 0.77 | 0.02 | -0.05 | -0.16 | -0.77 | 0.00 | |
| Net Cash Flow | 0.01 | 0.95 | -1.11 | 1.22 | -0.84 | -0.24 | -0.15 | 0.92 | 0.96 | 0.83 |
| Free Cash Flow | -3.58 | -0.18 | 0.20 | 1.50 | -3.11 | 0.02 | -0.38 | 0.52 | 1.56 | -0.21 |
| CFO/OP | -421% | 6% | 43% | 427% | -1,400% | 925% | -482% | 630% | -46% | -73% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 50.30 | 54.05 | 38.51 | 33.82 | 48.85 | 75.36 | 111.92 | 44.07 | 52.52 | 50.39 |
| Inventory Days | 26.47 | 27.55 | 35.78 | 40.85 | 48.28 | 42.65 | 38.29 | 43.94 | 48.42 | 43.87 |
| Days Payable | 1.60 | 4.30 | 38.17 | 32.86 | 27.52 | 39.67 | 39.26 | 79.66 | 111.95 | 38.61 |
| Cash Conversion Cycle | 75.17 | 77.29 | 36.13 | 41.81 | 69.61 | 78.34 | 110.95 | 8.34 | -11.00 | 55.65 |
| Working Capital Days | 568.05 | 572.30 | 539.17 | 492.62 | 382.08 | 321.59 | 324.18 | 284.60 | 116.85 | 87.67 |
| ROCE % | 5.35% | 2.39% | 2.19% | 0.88% | -0.08% | -0.80% | -0.74% | -38.23% | -25.67% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Business Segments Number ・Standalone data |
|
|||||||||
| Revenue contribution from Sale of Pharmaceuticals INR in '000s ・Standalone data |
||||||||||
| Number of Permanent Employees Number ・Standalone data |
||||||||||
| Trade Payables Turnover Ratio Times ・Standalone data |
||||||||||
| Trade Receivables Turnover Ratio Times ・Standalone data |
||||||||||
| Contribution of Interest Income to Turnover Percentage |
||||||||||
| Contribution of Trading in Food Products to Turnover Percentage |
||||||||||
| Number of R&D Labs Allotted Number ・Standalone data |
||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Submission of newspaper publication of corrigendum to the EGM Notice.
-
Shareholders Meeting- Corrigendum To The EGM Notice Of The EGM Scheduled To Be Held On 01St July, 2026.
17 Jun - Corrigendum to EGM notice revises 12,00,000-share preferential allotment, disqualifying two allottees and reallocating shares.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Jun - Newspaper Publication for intimation of special window.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 10 Jun
-
Shareholders Meeting- Notice Of Extra-Ordinary General Meeting Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
9 Jun - EGM on July 1, 2026 to approve 12 lakh equity shares at Rs.57, raising Rs.6.84 crore.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3]
NPL is a recent entrant in the life sciences research and pharmaceutical intermediates business. In FY24, the company altered its objectives to expand into the pharmaceutical bulk drug segment and healthcare research, analytics, and technology. Currently, it is engaged in pharmaceutical research and the production and trading of bulk drugs (Active Pharmaceutical Ingredients) as well as key starting materials and intermediates.